1. Pink Sheet

Requests For EMA PRIME Designation Fall But Improvements Are On The Way

 
• By Neena Brizmohun

While the European Medicines Agency and industry speculate as to why 2022 saw far fewer applications for a place on the priority medicines scheme for drugs for unmet medical needs, they are enthusiastic about improvements to the initiative that are set to be trialed soon.

The PRIME scheme can help drug developers understand how to generate robust data • Source: Shutterstock

The number of investigational drugs that the European Medicines Agency accepted onto PRIME, its scheme for promising medicines for unmet medical needs, fell to a record low in 2022. Thirteen products secured a place on the program, compared with the all-time high of 20 in 2020.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards